Overall Perfomance for "Lion Stock Alerts"
The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":
1 out of 10 campaigns closed down on first day
4 out of 10 campaigns closed up on first day
5 out of 10 campaigns had no net effect
ATNM Promotional Newsletter
The following is a newsletter released by "Lion Stock Alerts" promoting Actinium Pharmaceuticals, Inc.
Don't Want Anymore Emails
ATNM, our newest alert, released breaking news this morning that could be another growth catalyst for the company.
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with RR AML
Here are the highlights from this press release
Proof-of-concept Phase 1 data expected in 2H2021 will evaluate safety, response rates, MRD negativity and cytogenetic profiles
Complete response in patient with TP53 and other mutations and one partial response reported in patient with poor risk adverse cytogenetics reported in first dose cohort with subtherapeutic dose of Actimab-A with venetoclax
As the company further explained
Dr. Mark Berger, Actinium's Chief Medical Officer, said, We are encouraged by the strong progress we are making in this novel combination trial and excited to be studying Actimab-A with venetoclax. Venetoclax has emerged as a standard of care and backbone therapy for patients with AML who are both fit and unfit, however, patients with relapsed or refractory disease have poor outcomes and therefore need better treatment options. Based on the synergistic mechanism of action and preliminary clinical evidence from the first cohort, we are optimistic that Actimab-A in combination with venetoclax can improve outcomes for patients with relapsed or refractory disease using the unique targeted radiation mechanism of Actimab-A. We look forward to presenting data from this cohort of patients as well additional clinical data from the Phase 1 portion of the trial and working to advance this novel combination in the clinic.
Here are the companys comments from this press release
Sandesh Seth, Actinium's Chairman and CEO, added, This trial is an exciting evolution of our Actimab-A program and application of the isotope Actinium-225. Actinium-225 is a potent medical isotope that can kill a cancer cell with a single alpha particle hit, emits four alpha particles in its decay and can cause double strand DNA breaks for which cancer cells have no known repair or resistance mechanism. Its energy is also emitted over a very short path length equal to a few cells in diameter enabling precise cell killing while sparing normal cells to limit systemic toxicities. With clinical experience in nearly 150 patients, robust IP and a clinically validated supply chain, we are leaders in the rapidly growing field of targeted alpha radiotherapy and specifically Actinium-225. Through continued clinical progress and innovation driven by our RD efforts, we are committed to advancing our leadership position in the field of Actinium-225 based therapies and applying them with the goal of improving patient outcomes.
ATNM opened Wednesday at 8.58 and rallied to a high of 8.92, before closing the day at 8.30.
As the company further accomplishes its plans, it could position itself for increased opportunity.
Sources , , , , , , , , , , , , , , ,
Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
You should read and understand this disclaimer in its entirety before joining the website or emailblog list of LionStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 32321 for the distribution of this advertisement about ATNM dated 32521. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 12420 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated fifteen thousand dollars by bank wire transfer on 102920 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 101920 for the distribution of a prior advertisement about ATNM. Prior to this period, at the time of publication, we disclosed our compensation for the distribution of advertisements about ATNM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.
6020 Bent Pine Drive
Orlando FL 32828